{"id":"NCT01191255","sponsor":"Keryx Biopharmaceuticals","briefTitle":"A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis","officialTitle":"A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2013-01","completion":"2013-02","firstPosted":"2010-08-30","resultsPosted":"2014-12-10","lastUpdate":"2014-12-10"},"enrollment":441,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hyperphosphatemia","Kidney Failure"],"interventions":[{"type":"DRUG","name":"ferric citrate, ca acetate, sevelamer carbonate, placebo","otherNames":["PhosLo","Renvela","KRX-0502","Zerenex"]}],"arms":[{"label":"Active Control","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"KRX-0502 (Ferric Citrate)","type":"EXPERIMENTAL"}],"summary":"This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.","primaryOutcome":{"measure":"Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56)","timeFrame":"4 weeks","effectByArm":[{"arm":"Placebo-EAP","deltaMin":5.44,"sd":1.459},{"arm":"KRX-0502 (Ferric Citrate)-EAP","deltaMin":5.12,"sd":1.189}],"pValues":[{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","Israel","Puerto Rico"]},"refs":{"pmids":["40576086","26239948"],"seeAlso":["http://www.keryx.com"]},"adverseEventsSummary":{"seriousAny":{"events":114,"n":289},"commonTop":["Diarrhea","Nausea","Feces discolored","Vomiting","Vascular access complication"]}}